Safety and efficacy of peficitinib in Asian patients with rheumatoid arthritis who had an inadequate response or intolerance to methotrexate: results of a multicenter, randomized, double-blind, placebo-controlled phase 3 study

Effectiveness and safety of generic tofacitinib in spondyloarthritis: A real‐world retrospective analysis from India

(2023) Sanat Phatak et al.   International Journal of Rheumatic Diseases

Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach

(2022) Yoshiya Tanaka et al.   Nature Reviews Rheumatology

Oral surveillance and JAK inhibitor safety: the theory of relativity

(2022) Kevin L. Winthrop et al.   Nature Reviews Rheumatology

Pharmacokinetics and Safety of Single and Multiple Doses of Peficitinib (ASP015K) in Healthy Chinese Subjects

(2022) Xin Gao et al.   Drug Design Development and Therapy

Comparative safety of Janus kinase inhibitors and tumor necrosis factor inhibitors in patients undergoing treatment for rheumatoid arthritis

(2022) Yao‐Fan Fang et al.   International Journal of Rheumatic Diseases

The Safety Profile of Upadacitinib in Patients with Rheumatoid Arthritis in Japan

(2021) Kunihiro Yamaoka et al.   DRUG SAFETY

2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis

(2021) Liana Fraenkel et al.   ARTHRITIS CARE & RESEARCH

Peficitinib for the treatment of rheumatoid arthritis: an overview from clinical trials

(2020) Yoshiya Tanaka et al.   EXPERT OPINION ON PHARMACOTHERAPY

Efficacy and Safety of Baricitinib in Chinese Rheumatoid Arthritis Patients and the Subgroup Analyses: Results from Study RA-BALANCE

(2020) Yue Yang et al.   Rheumatology and Therapy

2018 update of the APLAR recommendations for treatment of rheumatoid arthritis

(2019) Chak Sing Lau et al.   International Journal of Rheumatic Diseases

A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis

(2019) Katie Bechman et al.   RHEUMATOLOGY

Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3)

(2019) Yoshiya Tanaka et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan

(2019) Tsutomu Takeuchi et al.   ANNALS OF THE RHEUMATIC DISEASES

A pooled analysis of the safety of tofacitinib as monotherapy or in combination with background conventional synthetic disease-modifying antirheumatic drugs in a Phase 3 rheumatoid arthritis population

(2018) Alan J. Kivitz et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Efficacy and Safety of Tofacitinib in Chinese Patients with Rheumatoid Arthritis

(2018) Zhan-Guo Li et al.   CHINESE MEDICAL JOURNAL

Peficitinib, a JAK Inhibitor, in the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate

(2017) A. J. Kivitz et al.   Arthritis & Rheumatology

Peficitinib, a JAK Inhibitor, in Combination With Limited Conventional Synthetic Disease-Modifying Antirheumatic Drugs in the Treatment of Moderate-to-Severe Rheumatoid Arthritis

(2017) Mark C. Genovese et al.   Arthritis & Rheumatology

Herpes Zoster and Tofacitinib: Clinical Outcomes and the Risk of Concomitant Therapy

(2017) Kevin L. Winthrop et al.   Arthritis & Rheumatology

A structured literature review of the burden of illness and unmet needs in patients with rheumatoid arthritis: a current perspective

(2016) Peter C. Taylor et al.   RHEUMATOLOGY INTERNATIONAL

Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study

(2015) Tsutomu Takeuchi et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and safety results from a Phase 3, randomized, placebo-controlled trial of subcutaneous golimumab in Chinese patients with active rheumatoid arthritis despite methotrexate therapy

(2015) Zhanguo Li et al.   International Journal of Rheumatic Diseases

Herpes Zoster and Tofacitinib Therapy in Patients With Rheumatoid Arthritis

(2014) Kevin L. Winthrop et al.   Arthritis & Rheumatology

The Pathogenesis of Rheumatoid Arthritis

(2011) Iain B. McInnes et al.   NEW ENGLAND JOURNAL OF MEDICINE

2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative

(2010) D. Aletaha et al.   ANNALS OF THE RHEUMATIC DISEASES